ArticleThe Journal of neuroscience nursing : journal of the American Association of Neuroscience Nurses
Initiating Apomorphine Therapy Without Antiemetic Pretreatment: Real-World Data From a Nurse-led Parkinson Disease Support Program.
Article in The Journal of neuroscience nursing : journal of the American Association of Neuroscience Nurses. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTrimethobenzamide has been the antiemetic of choice in the United States for people with Parkinson disease initiating subcutaneous apomorphine injection (SC-APO) therapy to rapidly manage OFF episodes. Following a cessation of trimethobenzamide production in 2021, SC‑APO was increasingly initiated without antiemetic pretreatment.The US labeling was subsequently updated in 2022 to recommend a lower SC-APO starting dose when initiating treatment without trimethobenzamide.
methodsData from the SC-APO Clinical Nurse Navigator support program were analyzed for new patient starts between January 2019 and March 2024, spanning periods before and after trimethobenzamide absence and SC-APO labeling changes. SC-APO starting dose patterns and 90-day treatment continuation were compared between patients who started with and without antiemetic pretreatment.
resultsAmong 2634 patients, SC-APO initiations without trimethobenzamide increased from 32.8% before cessation of production (2019-2020) to nearly 100% by the end of 2021. During 2021, most prescribers (56.7%) continued to use the 0.2 mL (2.0 mg) starting dose; following the 2022 labeling update, use of the 0.1 mL (1.0 mg) starting dose increased, reaching 86% by early 2024. The 90-day SC-APO continuation rates increased from 75.4% when used with trimethobenzamide pretreatment to 83.1% without it.
conclusionSC-APO is now routinely started without antiemetic pretreatment, with higher overall rates of early treatment continuation. Flexible starting doses and titration, together with nurse‑led patient education and support, may facilitate successful treatment initiation and continuation in contemporary clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.